Crestline Management LP purchased a new position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 29,025 shares of the biopharmaceutical company’s stock, valued at approximately $1,937,000. Crestline Management LP owned about 0.06% of Agios Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in AGIO. FMR LLC grew its position in shares of Agios Pharmaceuticals by 14.1% during the second quarter. FMR LLC now owns 7,227,331 shares of the biopharmaceutical company’s stock worth $371,846,000 after acquiring an additional 895,584 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Agios Pharmaceuticals by 23.8% during the second quarter. Vanguard Group Inc. now owns 3,214,770 shares of the biopharmaceutical company’s stock worth $165,401,000 after acquiring an additional 617,379 shares during the last quarter. BlackRock Inc. grew its position in shares of Agios Pharmaceuticals by 23.5% during the second quarter. BlackRock Inc. now owns 2,675,380 shares of the biopharmaceutical company’s stock worth $137,648,000 after acquiring an additional 508,306 shares during the last quarter. Janus Henderson Group PLC bought a new position in shares of Agios Pharmaceuticals during the second quarter worth about $20,423,000. Finally, Capital International Investors grew its position in shares of Agios Pharmaceuticals by 11.6% during the second quarter. Capital International Investors now owns 3,129,837 shares of the biopharmaceutical company’s stock worth $161,030,000 after acquiring an additional 325,310 shares during the last quarter. Institutional investors and hedge funds own 94.38% of the company’s stock.

In other Agios Pharmaceuticals news, CEO David P. Schenkein sold 80,000 shares of the company’s stock in a transaction dated Wednesday, October 4th. The shares were sold at an average price of $70.14, for a total value of $5,611,200.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO David P. Schenkein sold 35,000 shares of the company’s stock in a transaction dated Monday, September 18th. The shares were sold at an average price of $67.12, for a total transaction of $2,349,200.00. Following the completion of the sale, the chief executive officer now directly owns 35,000 shares of the company’s stock, valued at $2,349,200. The disclosure for this sale can be found here. Insiders sold 167,746 shares of company stock valued at $11,410,226 in the last ninety days. Corporate insiders own 5.43% of the company’s stock.

Shares of Agios Pharmaceuticals, Inc. (AGIO) opened at $61.42 on Tuesday. Agios Pharmaceuticals, Inc. has a 1-year low of $39.24 and a 1-year high of $72.73.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($1.59) earnings per share for the quarter, topping the consensus estimate of ($1.78) by $0.19. The business had revenue of $11.35 million during the quarter, compared to the consensus estimate of $10.85 million. Agios Pharmaceuticals had a negative net margin of 506.39% and a negative return on equity of 69.64%. The company’s quarterly revenue was up 26.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($1.63) earnings per share. research analysts anticipate that Agios Pharmaceuticals, Inc. will post -6.59 earnings per share for the current fiscal year.

AGIO has been the subject of several recent research reports. ValuEngine upgraded shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. Royal Bank of Canada initiated coverage on shares of Agios Pharmaceuticals in a research report on Thursday, September 14th. They set an “outperform” rating and a $78.00 price target for the company. Credit Suisse Group upped their price target on shares of Agios Pharmaceuticals from $61.00 to $66.00 and gave the stock an “outperform” rating in a research report on Thursday, November 2nd. J P Morgan Chase & Co restated a “buy” rating and set a $76.00 price target on shares of Agios Pharmaceuticals in a research report on Monday, September 18th. Finally, Oppenheimer set a $83.00 price objective on shares of Agios Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, November 17th. Three investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $75.70.

ILLEGAL ACTIVITY WARNING: This news story was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of international trademark and copyright laws. The legal version of this news story can be read at https://www.watchlistnews.com/crestline-management-lp-takes-1-94-million-position-in-agios-pharmaceuticals-inc-agio/1758593.html.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Want to see what other hedge funds are holding AGIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agios Pharmaceuticals, Inc. (NASDAQ:AGIO).

Institutional Ownership by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.